Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia

Recruiting N/A Interventional Study
Dystonia Movement Disorders Combined Dystonia Complex Dystonia
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
150 (estimated)
Sponsor
University Hospital, Strasbourg, France · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of d…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria - Index case: * Index case affected by familial dystonia (≥1 first-degree relative affected) and/or sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program. * Index case who has undergone short-read genome sequencing, which did n…
Contacts

Thomas WIRTH, Doctor

+33 3 88 12 89 19

thomas.wirth@chru-strasbourg.fr

CONTACT